Archive for November, 2014

PUBLIC RELEASE DATE:

11-Nov-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

New Rochelle, NY, November 11, 2014--Zelig Eshhar, PhD, The Weizmann Institute of Science and Sourasky Medical Center, and Carl H. June, MD, PhD, Perelman School of Medicine, University of Pennsylvania, are co-recipients of the Pioneer Award, recognized for lentiviral gene therapy clinical trials and for their leadership and contributions in engineering T-cells capable of targeting tumors with antibody-like specificity through the development of chimeric antigen receptors (CARs). Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers, is commemorating its 25th anniversary by bestowing this honor on the leading Pioneers in the field of cell and gene therapy selected by a blue ribbon panel* and publishing a Pioneer Perspective by the award recipients. The Perspectives by Dr. Eshhar and Dr. June are available free on the Human Gene Therapy website at http://www.liebertpub.com/hgt until December 11, 2014.

In his Pioneer Perspective entitled "From the Mouse Cage to Human Therapy: A Personal Perspective of the Emergence of T-bodies/Chimeric Antigen Receptor T Cells" Professor Eshhar chronicles his team's groundbreaking contributions to the development of the CAR T-cell immunotherapeutic approach to treating cancer. He describes the method's conceptual development including initial proof-of-concept, and the years of experimentation in mouse models of cancer. They first tested the CAR T-cells on tumors transplanted into mice then progressed to spontaneously developing cancers in immune-competent mice, which Dr. Eshhar describes as "a more suitable model that faithfully mimics cancer patients." He recounts successful antitumor effects in mice with CAR modified T-cells injected directly into tumors, with effects seen at the injection site and at sites of metastasis, and even the potential of the CAR T-cells to prevent tumor development.

Dr. Carl H. June has led one of the clinical groups that has taken the CAR therapeutic strategy from the laboratory to the patients' bedside, pioneering the use of CD19-specific CAR T-cells to treat patients with leukemia. In his Pioneer Perspective, "Toward Synthetic Biology with Engineered T Cells: A Long Journey Just Begun" Dr. June looks back on his long, multi-faceted career and describes how he combined his knowledge and research on immunology, cancer, and HIV to develop successful T-cell based immunotherapies. Among the lessons Dr. June has embraced throughout his career are to follow one's passions. He also says that "accidents can be good: embrace the unexpected results and follow up on these as they are often times more scientifically interesting than predictable responses from less imaginative experiments."

"These two extraordinary scientists made seminal contributions at key steps of the journey from bench to bedside for CAR T-cells," says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.

###

*The blue ribbon panel of leaders in cell and gene therapy, led by Chair Mary Collins, PhD, MRC Centre for Medical Molecular Virology, University College London selected the Pioneer Award recipients. The Award Selection Committee selected scientists that had devoted much of their careers to cell and gene therapy research and had made a seminal contribution to the field--defined as a basic science or clinical advance that greatly influenced progress in translational research.

About the Journal

Visit link:
Zelig Eshhar and Carl H. June honored for research on T cell engineering for cancer immunotherapy

Next time you pour a glass of wine, raise a toast to the 30-milion-year-old viruses that have contributed to the genetic make-up of modern grapes.

A team of UQ-led plant scientists has discovered that the Pinot Noir grape variety owes a significant part of its genetic heritage to ancient plant viruses.

In a study published in Nature Communications, Dr Andrew Geering and colleagues have mapped the presence of 30-million-year-old viruses in Pinot Noir DNA.

Viruses are usually a curse to farmers because of the damage they cause to crops, but this study also suggests they play a vital evolutionary role.

Dr Geering, a plant pathologist at the UQs Queensland Alliance for Agriculture and Food Innovation, said most flowering plant species, even the most primitive ones, contain sequence signatures of viruses in their genetic material.

Animals can move to avoid threats but because plants are anchored to the ground they are obliged to adapt to environmental pressures, such as those brought about by drought or grazing, using novel strategies.

Plants cope with such threats by acquiring new biochemical pathways or growth habits.

Pulling new genetic material from the environment, such as from viruses that infect the plant, means evolution can be sped up considerably.

Much like humans, plants are regularly exposed to harmful chemicals or radiation, which can cause damaging and heritable mutations to their genes which, if left unrepaired, could be lethal to their descendants.

Fortunately, there are special mechanisms to repair these mutations. Its during this repair procedure that foreign DNA such as that originating from viruses can be inserted into the plants own genetic code, much like using putty to fill a crack in the wall.

Read this article:
Our wine owes a debt to ancient viruses

Contact Information

Available for logged-in reporters only

Newswise (NEW YORK November 10) The Icahn School of Medicine at Mount Sinais Institute for Personalized Medicine is launching a study designed to learn whether patients, who are aware of their genetic predisposition to chronic kidney disease, are more inclined to engage in proactive lifestyle modification with their primary care physician.

Chronic kidney disease affects about 26 million American adults. Many studies have shown that African Americans are up to seven times more likely than any other population to develop high blood pressure and subsequent complications, such as kidney disease. A large fraction of the kidney disease disparity is attributable to variations, or differences, in a single gene called apolipoprotein L1 (APOL1). In Mount Sinais specialized laboratory, variations in the APOL1 gene can be identified with a simple blood test.

Erwin Bottinger, MD, Director, Charles Bronfman Institute for Personalized Medicine in the Icahn School of Medicine at Mount Sinai is one of the studys Principal Investigators. Many patients do not have their blood pressure adequately controlled to minimize the risk for complications such as kidney disease. We will test whether sharing genetic risk information with patients and alerting their doctors through a patient's electronic health record, will achieve better control of blood pressure to reduce kidney disease risk.

Dr. Bottinger and Co-Principal Investigator Carol Horowitz, MD, MPH, are seeking to enroll approximately two thousand African American participants with hypertension for their year-long study: Genetic testing to Understand and Address Renal Disease Disparities (The GUARDD Study). Funded by the National Human Genome Research Institute (NHGRI) the study will be conducted in a network of community health centers and primary care facilities in Northern Manhattan and the South Bronx, affiliated with the Icahn School of Medicines Institute for Family Health and at primary care facilities of The Mount Sinai Health System.

At the first study visit, all study participants will be asked to complete medical and family health histories, blood pressure, height, and weight measurements. If eligible, each individual will be randomly assigned to one of two groups. Group 1 will have blood drawn for genetic testing and return within 4 weeks later to discuss the results with a member of the research team. They will also be given printed information to share with their primary care physician. Those participants will return after 3 months and 12 months for a blood pressure check and to complete follow-up surveys.

Individuals in Group 2 will receive the genetic testing until the end of the study but will be asked to return at 3 and 12 months for the same measurements as those in Group 1. Primary care providers for patients enrolled in the study will also receive the results of the APOL1 genetic test and information about the test through alerts in the patients electronic medical record.

We are translating the latest scientific developments for both patients and their primary care physicians, says Dr. Horowitz. While we cant guarantee results, we are hopeful participants who know they carry the APOL1 gene variant will engage in proactive behaviors, under their doctors supervision to forestall renal failure often associated with hypertension.

Neil Calman, MD, President and Chief Executive Officer of the Institute for Family Health, and Professor and Chair of Family Medicine and Community Health at Mount Sinai said, Armed with this genetic information, African Americans with high blood pressure who carry variations in this gene will be able to focus on the management of their high blood pressure with their primary care providers, helping to prevent the onset of the devastating effects of kidney failure.

Go here to read the rest:
Study to Assess if Knowing About Genetic Risk For Kidney Disease Changes a Person's Lifestyle

PUBLIC RELEASE DATE:

11-Nov-2014

Contact: Scott LaFee slafee@ucsd.edu 619-543-6163 University of California - San Diego @UCSanDiego

With the help of mouse models, induced pluripotent stem cells (iPSCs) and the "tooth fairy," researchers at the University of California, San Diego School of Medicine have implicated a new gene in idiopathic or non-syndromic autism. The gene is associated with Rett syndrome, a syndromic form of autism, suggesting that different types of autism spectrum disorder (ASD) may share similar molecular pathways.

The findings are published in the Nov. 11, 2014 online issue of Molecular Psychiatry.

"I see this research as an example of what can be done for cases of non-syndromic autism, which lack a definitive group of identifying symptoms or characteristics," said principal investigator Alysson Muotri, PhD, associate professor in the UC San Diego departments of Pediatrics and Cellular and Molecular Medicine. "One can take advantage of genomics to map all mutant genes in the patient and then use their own iPSCs to measure the impact of these mutations in relevant cell types. Moreover, the study of brain cells derived from these iPSCs can reveal potential therapeutic drugs tailored to the individual. It is the rise of personalized medicine for mental/neurological disorders."

But to effectively exploit iPSCs as a diagnostic tool, Muotri said researchers "need to compare neurons derived from hundreds or thousands of other autistic individuals." Enter the "Tooth Fairy Project," in which parents are encouraged TO register for a "Fairy Tooth Kit," which involves sending researchers like Muotri a discarded baby tooth from their autistic child. Scientists extract dental pulp cells from the tooth and differentiate them into iPSC-derived neurons for study.

"There is an interesting story behind every single tooth that arrives in the lab," said Muotri.

The latest findings, in fact, are the result of Muotri's first tooth fairy donor. He and colleagues identified a de novo or new disruption in one of the two copies of the TRPC6 gene in iPSC-derived neurons of a non-syndromic autistic child. They confirmed with mouse models that mutations in TRPC6 resulted in altered neuronal development, morphology and function. They also noted that the damaging effects of reduced TRPC6 could be rectified with a treatment of hyperforin, a TRPC6-specific agonist that acts by stimulating the functional TRPC6 in neurons, suggesting a potential drug therapy for some ASD patients.

The researchers also found that MeCP2 levels affect TRPC6 expression. Mutations in the gene MeCP2, which encodes for a protein vital to the normal function of nerve cells, cause Rett syndrome, revealing common pathways among ASD.

Read more from the original source:
Multiple models reveal new genetic links in autism

PUBLIC RELEASE DATE:

11-Nov-2014

Contact: Raeka Aiyar, Ph.D. press@genetics-gsa.org 202-412-1120 Genetics Society of America @GeneticsGSA

The Genetics Society of America (GSA) announced today that it is partnering with Cold Spring Harbor Laboratory (CSHL) Press to assist authors in submitting unpublished manuscripts to bioRxiv, a fast-growing preprint server for the life sciences.

GENETICS and G3: Genes|Genomes|Genetics, the journals of the GSA, will this month enable authors to submit a manuscript for peer review to either journal and, simultaneously, to post the manuscript as a preprint on bioRxiv. The bioRxiv preprint will be immediately available to the public, citable via a Digital Object Identifier (DOI), and open for reader comments and feedback.

This simple, optional transfer is available through Bench>Press, HighWire's electronic manuscript submission and peer-review workflow system. Using a streamlined Bench>Press workflow developed by HighWire for bioRxiv, author manuscripts are immediately available to the scientific community for feedback as they are submitted for peer review. For those manuscripts that go on to be accepted by either GSA journal, bioRxiv will feature an updated link to the final version of the article, which incorporates revisions from the formal peer-review and peer-editing process.

"With preprint deposits, scientists can communicate their findings earlier, whether they seek feedback, collaboration, or to spread the news of their latest work," says Stephen I. Wright, PhD, Senior Editor for Population and Evolutionary Genetics at G3, GENETICS Associate Editor, and Associate Professor in the Department of Ecology and Evolutionary Biology at the University of Toronto. "Hearing about and receiving feedback on the very latest work prior to publication was historically the domain only of scientific meetings, but preprint archives now allow for continual rapid dissemination and feedback. In the end, when combined with formal peer-review and peer-editing, the reach, findings, and impact of the science ends up even stronger."

Welcoming the announcement, John R. Inglis, PhD, Executive Director and Publisher at Cold Spring Harbor Laboratory says: "In just a year, bioRxiv has become, for many scientists working in genetics and genomics, a significant source of new information in preprint form. So we are delighted that GENETICS and G3, the journals of the forward-looking Genetics Society of America, are the first to partner with bioRxiv to give authors the chance to rapidly share their findings and readers an early opportunity to critically evaluate new observations in their field."

"We're thrilled to participate in this initiative, in particular because many of our authors already use bioRxiv, especially in population and evolutionary genetics" says Tracey DePellegrin, Executive Editor for the GSA Journals. "It's about listening to members of the research community and figuring out ways to help disseminate and discuss their work. Authors who choose to deposit their work in bioRxiv will enjoy greater visibility and feedback and, if the submitted manuscript progresses to peer-review, the benefits of thoughtful, thorough review and peer-editing. This partnership reflects our commitment to fostering open conversations about science, while at the same time, underscoring the importance of academic editors as peers. Our practicing scientist editors synthesize peer-reviews into a letter that clearly lets authors know what is expected in a revised manuscript. Manuscript deposits in bioRxiv allow early and open discussions on the work, including conversations about the evolution of an initial manuscript draft into a published research article."

###

Read more from the original source:
Genetics Society of America to assist authors in depositing preprints into CSHL's bioRxiv

Contact Information

Available for logged-in reporters only

Newswise BETHESDA, MD The Genetics Society of America (GSA) announced today that it is partnering with Cold Spring Harbor Laboratory (CSHL) Press to assist authors in submitting unpublished manuscripts to bioRxiv, a fast-growing preprint server for the life sciences.

GENETICS and G3: Genes|Genomes|Genetics, the journals of the GSA, will this month enable authors to submit a manuscript for peer review to either journal and, simultaneously, to post the manuscript as a preprint on bioRxiv. The bioRxiv preprint will be immediately available to the public, citable via a Digital Object Identifier (DOI), and open for reader comments and feedback.

This simple, optional transfer is available through Bench>Press, HighWire's electronic manuscript submission and peer-review workflow system. Using a streamlined Bench>Press workflow developed by HighWire for bioRxiv, author manuscripts are immediately available to the scientific community for feedback as they are submitted for peer review. For those manuscripts that go on to be accepted by either GSA journal, bioRxiv will feature an updated link to the final version of the article, which incorporates revisions from the formal peer-review and peer-editing process.

With preprint deposits, scientists can communicate their findings earlier, whether they seek feedback, collaboration, or to spread the news of their latest work, says Stephen I. Wright, PhD, Senior Editor for Population and Evolutionary Genetics at G3, GENETICS Associate Editor, and Associate Professor in the Department of Ecology and Evolutionary Biology at the University of Toronto. Hearing about and receiving feedback on the very latest work prior to publication was historically the domain only of scientific meetings, but preprint archives now allow for continual rapid dissemination and feedback. In the end, when combined with formal peer-review and peer-editing, the reach, findings, and impact of the science ends up even stronger.

Welcoming the announcement, John R. Inglis, PhD, Executive Director and Publisher at Cold Spring Harbor Laboratory says: In just a year, bioRxiv has become, for many scientists working in genetics and genomics, a significant source of new information in preprint form. So we are delighted that GENETICS and G3, the journals of the forward-looking Genetics Society of America, are the first to partner with bioRxiv to give authors the chance to rapidly share their findings and readers an early opportunity to critically evaluate new observations in their field.

Were thrilled to participate in this initiative, in particular because many of our authors already use bioRxiv, especially in population and evolutionary genetics says Tracey DePellegrin, Executive Editor for the GSA Journals. Its about listening to members of the research community and figuring out ways to help disseminate and discuss their work. Authors who choose to deposit their work in bioRxiv will enjoy greater visibility and feedback and, if the submitted manuscript progresses to peer-review, the benefits of thoughtful, thorough review and peer-editing. This partnership reflects our commitment to fostering open conversations about science, while at the same time, underscoring the importance of academic editors as peers. Our practicing scientist editors synthesize peer-reviews into a letter that clearly lets authors know what is expected in a revised manuscript. Manuscript deposits in bioRxiv allow early and open discussions on the work, including conversations about the evolution of an initial manuscript draft into a published research article.

* * *

About the Genetics Society of America (GSA) Founded in 1931, the Genetics Society of America (GSA) is the professional scientific society for genetics researchers and educators. The Societys more than 5,000 members worldwide work to deepen our understanding of the living world by advancing the field of genetics, from the molecular to the population level. GSA promotes research and fosters communication through a number of GSA-sponsored conferences including regular meetings that focus on particular model organisms. GSA publishes two peer-reviewed, peer-edited scholarly journals: GENETICS, which has published high quality original research across the breadth of the field since 1916, and G3: Genes|Genomes|Genetics, an open-access journal launched in 2011 to disseminate high quality foundational research in genetics and genomics. The Society also has a deep commitment to education and fostering the next generation of scholars in the field. For more information about GSA, please visit http://www.genetics-gsa.org.

Continue reading here:
Genetics Society of America First to Partner with Cold Spring Harbor Laboratory Press to Assist Authors in Depositing ...

The ASTIS trial (Autologous Stem cell Transplantation International Scleroderma), launched in 2001, evaluated the efficacy of autologous haematopoietic stem cell transplantation (HSCT) in patients with systemic sclerosis. A key point to safe use of HSCT is a correct evaluation of cardiac condition, and a close follow up for cardiac complications. In a letter to the Editor published in The Journal of the American Medical Association, entitled Cardiac Assessment Before Stem Cell Transplantation for Systemic Sclerosis, Dr. Burt at the Division of Immunotherapy, Northwestern University and colleagues highlight the importance of performing extensive cardiopulmonary screening in patients with severe forms of systemic sclerosis before administrating HSCT.

HSCT therapy first involves harvestingpatients stem cells. Since Scleroderma, also known as systemic sclerosis, is a chronic systemic autoimmune disease (autoimmune diseases are characterized by a hyper-reactive response of the immune response against substances, and tissues normally present in the body), thesecond step of the process involves destroyingpatients hyper-reactive immune system usingchemotherapy. Afterward, the patients harvested stem cells will be injected back into the body. The objective is to reset the patient immune system to normal standards and thus stop the process of scleroderma.

Systemic sclerosis is associated with many cardiac complications, including intrinsic myocardial ischemia and fibrosis, left ventricular diastolic dysfunction, and pericardial disease. While the criteria for exclusion inthe ASTIS trial was mean pulmonary artery pressure greater than 50 mm Hg by echo-cardiogram or cardiac catheterization, theauthors emphasize that this does not exclude pulmonary arterial hypertension. Despite the fact that2009 guidelines updatedtheir information and described pulmonary arterial hypertension as a mean pulmonary artery pressure higher than 25 mm Hg, the authors cautioned that a significant amount of attention has to be dedicated toassessing cardiac risks in these patients to prevent treatment-related mortality.

Link:
New Insights For Cardiac Assessment Before Administering ...

AP Glowing: Model Kate Moss

For someone who has mature skin, it is annoying watching 20-somethings with blemish-less complexions worrying about wrinkles and crowfeet. No one seems to be concerned about those over 40 who, for the better part of their 20s and 30s, were busy cooking, cleaning and washing up instead of pandering to their skin.

So when Page 3 Salon, in Race Course, issued an invitation to try its new award-winning skin therapy for mature skin all the way from Spain, one jumped at it. It is supposed to be the same treatment celebrities such as Elton John, Penelope Cruz, Jemima Khan and Kate Moss use to keep their skin glowing and young.

If you have mature skin, this treatment is the one for you, says a spokesperson for the brand Skeyndor (meaning golden skin), who was in Coimbatore recently to promote the product and train the beauty therapists at Page 3 the correct way to use the products. Skeyndor has over 200 products to suit other skin types, too. R&D is the companys strength and it is also one of the first in the cosmetic industry to use nano-technology for skin care.

She says, comfortingly, that my skin is still not too bad and sits me down to explain what I can do to keep it from aging too fast.

The special facial that is recommended for me uses products that are gentle on the skin and one particular treatment that has the same effect as Botox. And, without being invasive at all. Before the facial commences a photograph is taken focussing on the problem areas of the skin. And once the hour-plus, soothing treatment is done (so soothing that I fall asleep), it is time for another photograph. And strangely enough, even the sceptic in me has to admit there is a discernible difference in skin texture. It felt more elastic and from the photographs I could tell there were fewer few lines.

The beautician recommends a series of facials at regular intervals (depending on the condition of the skin and the amount of repair it needs). The salon will make a schedule for you and remind you when it is time to come for a treatment. The salon also provides you with tips on home care. Page 3 offers two high-end special facials. Both sound tempting: One is called Revisit your youth and the other Turn Back Time.

Anyone who is 35 plus can go for the Turn Back Time facial, says Shan of Page 3. This treatment is supposed to arrest ageing and promote the production of epidermal stem cells. It holds off the fine lines, wrinkles and sagging. Revisit Your Youth on the other hand is corrective. It promises to reduce the crows feet and lines that have already appeared on your face. The products in this line work like Botox without being invasive, says Shan.

The products are available at the salon. For appointments and details call:0422-4393333/4223331

What is mature skin?

Visit link:
A mature approach

Cell Therapy (Lemon Water)
Cell Therapy (Lemon Water) Symmetry Composer: Tha Professa Auto-generated by YouTube.

By: Various Artists - Topic

Go here to read the rest:
Cell Therapy (Lemon Water) - Video

The day Olivia Cox was diagnosed with Type 1 diabetes at age 16, her mother vowed to find a cure.

"I said to her, "there's someone walking this Earth who has been cured of diabetes, and I'm going to find him," Ruth Cox said.

Cox's search started with a call to Harvard University and ended with a family trip to Lima, Peru. It was at a clinic there that now 18-year-old Olivia and her father, Jeff, 54, who also has diabetes, received an infusion of stem cells designed to wipe out diabetes in their bodies or, at the very least, lessen its impact. The treatment illegal in the United States cost $70,000 for both father and daughter. Two months later, the Niskayuna family is waiting for a transformation and wondering if, in their desperation for a cure, they were snookered by false promises.

Because stem cells can be programmed to become anything from heart muscle to toenails, stem cell therapy can hypothetically be used to treat anything, from baldness to Lou Gehrig's Disease. But the study of regenerative medicine is still nascent in the United States, where it is restricted to procedures that use the patient's own cells, and it has been primarily used in treating cancer a procedure that saved Ruth Cox 13 years ago, when she had breast cancer.

Stem cell treatment using donor cells is more common elsewhere in the world, but with varying results and none that could be described as a cure. An executive order from President Barack Obama opened up funding for stem cell research and there are now more than 4,000 clinical trials under way, some on animals and some recruiting people with various ailments.

The American Diabetes Association strongly supports stem cell research, according to a statement posted on its website, which reads in part:

"Scientists from across the United States and throughout the world, including those involved with the American Diabetes Association believe that stem cell research, especially embryonic stem cell research, holds great promise in the search for a cure and better treatments for diabetes."

Jeff Cox, diagnosed with Type 1 diabetes when he was 11, has suffered none of the complications that often come with the disease neuropathy, loss of vision and heart disease. But Cox said living with diabetes is hell. He pricks his finger at least a dozen times a day to check his blood sugar level, because it is a more precise reading than the glucose monitor he wears. He also wears a pump that he programs to inject him with insulin automatically based on his diet and exercise each day. All the therapies used to treat diabetes are designed to intervene where the pancreas has gone awry.

In Type 1 diabetes, the pancreas doesn't produce insulin due to an autoimmune attack against the beta cell that produces insulin the hormone that converts glucose into energy our bodies need to survive. The Coxes didn't want their daughter to face a lifetime of managing her diabetes. They wanted a cure, and they were willing to take a risk to find it.

In order to treat diabetes with stem cell therapy, pancreatic stem cells isolated from umbilical cord blood that are programmed to produce insulin, plus autologous mesenchymal stem cells from the patient's bone marrow, are injected. Once in the pancreas, the cells are supposed to replicate themselves, gradually replacing the non-insulin producing cells in the host's pancreas. The treatment is conducted in Peru, China, Russia and India and elsewhere, but Zubin Master, a bioethicist at Albany Medical College, said the risks of traveling abroad for stem cell therapy range from paying for an expensive treatment that doesn't work, to cancer and death.

Read more:
Family's desperate bet on a diabetes cure

PUBLIC RELEASE DATE:

10-Nov-2014

Contact: Ccile Martinat CMARTINAT@istem.fr 33-603-855-477 INSERM (Institut national de la sant et de la recherche mdicale) @inserm

This news release is available in French.

The motor neurons that innervate muscle fibres are essential for motor activity. Their degeneration in many diseases causes paralysis and often death among patients. Researchers at the Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (I-Stem - Inserm/AFM/UEVE), in collaboration with CNRS and Paris Descartes University, have recently developed a new approach to better control the differentiation of human pluripotent stem cells, and thus produce different populations of motor neurons from these cells in only 14 days. This discovery, published in Nature Biotechnology, will make it possible to expand the production process for these neurons, leading to more rapid progress in understanding diseases of the motor system, such as infantile spinal amyotrophy or amyotrophic lateral sclerosis (ALS).

Human pluripotent stem cells have the ability to give rise to every cell in the body. To understand and control their potential for differentiation in vitro is to offer unprecedented opportunities for regenerative medicine and for advancing the study of physiopathological mechanisms and the quest for therapeutic strategies. However, the development and realisation of these clinical applications is often limited by the inability to obtain specialised cells such as motor neurons from human pluripotent stem cells in an efficient and targeted manner. This inefficiency is partly due to a poor understanding of the molecular mechanisms controlling the differentiation of these cells.

Inserm researchers at the Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (I-Stem - Inserm/French Muscular Dystrophy Association [AFM]/University of vry Val d'Essonne [UEVE]), in collaboration with CNRS and Paris-Descartes University, have developed an innovative approach to study the differentiation of human stem cells and thus produce many types of cells in an optimal manner.

"The targeted differentiation of human pluripotent stem cells is often a long and rather inefficient process. This is the case when obtaining motor neurons, although these are affected in many diseases. Today, we obtain these neurons with our approach in only 14 days, nearly twice as fast as before, and with a homogeneity rarely achieved," explains Ccile Martinat, an Inserm Research Fellow at I-Stem.

To achieve this result, the researchers studied the interactions between some molecules that control embryonic development. These studies have made it possible to both better understand the mechanisms governing the generation of these neurons during development, and develop an optimal "recipe" for producing them efficiently and rapidly.

"We are now able to produce and hence study different populations of neurons affected to various degrees in diseases that cause the degeneration of motor neurons. We plan to study why some neurons are affected and why others are preserved," adds Stphane Nedelec, an Inserm researcher in Ccile Martinat's team.

See original here:
Production of human motor neurons from stem cells is gaining speed

People who carry a particular type of gene have a natural resistance against typhoid fever, Australian-led research has found, which could lead to a more effective vaccine against the disease.

Lead researcher Dr Sarah Dunstan, of the University of Melbourne, says the study screened the human genome for genes linked to the susceptibility to or resistance from typhoid.

It was found that carrying a particular form of the HLA-DRB1 gene provides natural resistance against typhoid fever.

The ultimate cure for typhoid is eliminating the conditions that allow it to thrive - unclean water and poor sanitation - but Dr Dunstan says this is a long way from reality and her team's research could help people now.

It is particularly urgent because typhoid bacteria are increasingly more resistant to antibiotic treatment, and the current vaccine is only moderately effective.

"By doing this research we can try to tackle this problem right now by trying to understand the disease process more," she said.

"Hopefully that will enable us to create more effective vaccines so we can try to help people who are suffering this disease now."

The research collaboration included the Nossal Institute of Global Health at the University of Melbourne, Genome Institute of Singapore and Oxford University Clinical Research Units in Vietnam and Nepal.

TYPHOID'S TORMENT

New

Go here to see the original:
Aust research could help cure typhoid

PUBLIC RELEASE DATE:

10-Nov-2014

Contact: Elizabeth Dowling newsmedia@mssm.edu 212-241-9200 The Mount Sinai Hospital / Mount Sinai School of Medicine @mountsinainyc

Regulation of a single, specific gene in a brain region related to drug addiction and depression is sufficient to reduce drug and stress responses, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published October 27 online in the journal Nature Neuroscience.

The Mount Sinai study focuses on epigenetics, the study of changes in the action of human genes caused, not by changes in DNA code we inherit from our parents, but instead by molecules that regulate when, where and to what degree our genetic material is activated.

Previous research has found links between epigenetic regulation and the diseases of drug addiction and depression, in both human patients and animal models. Such regulation derives, in part, from the function of transcription factors, specialized proteins that bind to specific DNA sequences and either encourage or shut down the expression of a given gene.

Using mouse models of human depression, stress and addiction, the current research team introduced synthetic- transcription factors into a brain region called the nucleus accumbens at a single gene called FosB, which has been linked by past studies to both addiction and depression. They found that changes to this single gene brought on by the transcription factors made the study mice more resilient to stress and less likely to become addicted to cocaine.

Found in every cell of the body, DNA contains genes and the instructions needed for an organism to develop and survive. To carry out these functions, DNA sequences are converted into messages that "tell" cells which proteins to make, dictating the specific function of a given cell. While all cells contain the DNA that codes for every gene, most genes are not activated at all times. The expression of a given gene depends on the action of transcription factors, proteins that regulate the structure of DNA within the cell, allowing some genes to be active and others to be repressed. Transcription factors act by epigenetic mechanisms: chemically modifying either the DNA itself, or the histone proteins packaged around DNA that change shape given the right signal to make stretches of DNA available to the protein building machinery.

"Earlier work in our laboratory found that several transcription factors and downstream epigenetic modifications are altered by exposure to drugs or to stress and that these changes, in turn, control gene expression," says Eric J. Nestler, MD, PhD, Nash Family Professor, Chair of the Department of Neuroscience and Director of the Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai, who led the study. "But because such epigenetic regulation occurs at hundreds or thousands of genes, until now it had been impossible to determine the difference between the mere presence of an epigenetic modification and its functional relevance to neuropsychiatric disease."

To directly address this issue, Elizabeth A Heller, PhD, lead author on the paper, developed an innovative method to control epigenetic regulation of FosB. Dr. Heller introduced synthetic transcription factors called Zinc Finger Proteins (ZFPs), designed to target only a single gene out of 20,000, by incorporating them into a virus and injecting that virus into the reward-related brain region. Study results indicate that upon binding to that one gene, the FosB-ZFPs modified histones in the vicinity of the FosB gene, in order to either activate (turn on) or repress (turn off) expression.

Follow this link:
Changes in a single gene's action can control addiction and depression-related behaviors

PUBLIC RELEASE DATE:

10-Nov-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

New Rochelle, NY, November 10, 2014--To understand their risk for hereditary forms of cancer, such as breast and colon cancer, women need to know their family history. The design and effectiveness of a 20-minute skills-based intervention that can help women better communicate with relatives and gather and share information about cancer family history is described in a study in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Women's Health website at http://online.liebertpub.com/doi/full/10.1089/jwh.2014.4754 until December 10, 2014.

In the article "The KinFact Intervention - A Randomized Controlled Trial to Increase Family Communication About Cancer History," Joann Bodurtha, MD, and coauthors from Johns Hopkins University (Baltimore, MD), Virginia Commonwealth University (Richmond, VA), and Boston University (MA), describe the Keeping Information about Family Cancer Tune-up Program (KinFact) intervention.

KinFact participants were significantly more likely to gather and share family cancer information with relatives and to communicate with them more often than were women who instead received a handout about lowering cancer risk and cancer screening. The authors found that the effectiveness of KinFact varied depending on whether women were pregnant and on their level of genetic literacy.

"Communication within families about cancer diagnoses and risk is difficult, and interventions like KinFact are useful to better understand patients' family health risks," says Susan G. Kornstein, MD, Editor-in-Chief of Journal of Women's Health, Executive Director of the Virginia Commonwealth University Institute for Women's Health, Richmond, VA, and President of the Academy of Women's Health.

###

About the Journal

Journal of Women's Health, published monthly, is a core multidisciplinary journal dedicated to the diseases and conditions that hold greater risk for or are more prevalent among women, as well as diseases that present differently in women. The Journal covers the latest advances and clinical applications of new diagnostic procedures and therapeutic protocols for the prevention and management of women's healthcare issues. Complete tables of content and a sample issue may be viewed on the Journal of Women's Health website at http://www.liebertpub.com/jwh. Journal of Women's Health is the official journal of the Academy of Women's Health and the Society for Women's Health Research.

Read the rest here:
New approach helps women talk to their families about cancer risk

PUBLIC RELEASE DATE:

10-Nov-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

New Rochelle, NY, November 10, 2014--The Centers for Disease Control and Prevention (CDC) lists numerous potential alternative sources of HIV transmission in addition to the known classical modes for acquiring the AIDS virus. Although manicure instruments is not on this list of alternative sources, a case of HIV transmission that may be linked to sharing of manicure instruments is presented in AIDS Research and Human Retroviruses, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article appears in special issue on HIV Prevention Science and is available free on the AIDS Research and Human Retroviruses website at http://online.liebertpub.com/doi/full/10.1089/aid.2014.0264 until December 10, 2014.

In the article "An HIV-1 Transmission Case Possibly Associated with Manicure Care," Elaine Monteiro Matsuda and coauthors from Santo Andr AIDS Program, Adolfo Lutz Institute, and University of So Paulo, Brazil, describe the case of a 22-year-old woman who had advanced HIV infection but no apparent risk factors for acquiring HIV. She reported having shared manicure instruments years before with a cousin who was later found to be HIV-positive. Genetic analysis of the viruses from both patients suggests that they shared a common viral ancestor, indicating the possibility that HIV was transmitted via the manicure instruments.

"HIV is not transmitted by casual contact, such as sharing eating utensils, or drinking from the same water glass," says AIDS Research and Human Retroviruses Basic Sciences Editor/Sequence Notes Brian Foley, PhD, HIV Sequence Database, Los Alamos National Laboratory, NM. "This transmission of HIV by shared manicure equipment is a very rare event that should serve not to make people fear HIV or contact with HIV-infected people. It should make people aware that sharing any utensils with possible blood-blood contact, such as needles used for drugs, tattoos, or acupuncture can result in transmission of viruses such as hepatitis C (HCV) and HIV. In addition, there are other common viruses and bacteria that can also be spread by sharing equipment without proper disinfection between users."

###

About the Journal

AIDS Research and Human Retroviruses, published monthly in print and online, presents papers, reviews, and case studies documenting the latest developments and research advances in the molecular biology of HIV and SIV and innovative approaches to HIV vaccine and therapeutic drug research, including the development of antiretroviral agents and immune-restorative therapies. The content also explores the molecular and cellular basis of HIV pathogenesis and HIV/HTLV epidemiology. The Journal features rapid publication of emerging sequence information and reports on clinical trials of emerging HIV therapies. Tables of content and a sample issue may be viewed on the AIDS Research and Human Retroviruses website at http://www.liebertpub.com/aid.

About the Publisher

Follow this link:
Can HIV be transmitted via manicure instruments?

The first close look at the genetic code of a domestic cat suggests that food rewards from people brought man and feline together, based on genome variations associated with memory and reward behaviors.

The study also identified how cats evolved to lead solitary, meat-eating lives, and finds that, perhaps unsurprisingly, cats arent quite as domesticated as dogs.

The domestic cat genome shows a relatively small number of changed genetic regions compared to domesticated dogs, said Wesley Warren of the Genome Institute at Washington University School of Medicine in Saint Louis, who led the study. Cats are clearly still very independent in their behaviors, and, importantly, still interbreed with wild populations.

Americans alone own 96 million cats, according to the Humane Society. The findings, published yesterday in the Proceedings of the National Academy of Sciences, may help researchers better understand and treat cat diseases, including illnesses shared with humans, such as kidney calcification.

Cat domestication began about 9,000 years ago, an estimate based on the remains of a cat laid carefully next to those of a human at an ancient Cyprus burial site, though most of the 30 to 40 cat breeds today originated just 150 years ago, previous research has found.

To examine what happened during that domestication process, Warren and colleagues sequenced the genome of a female Abyssinian cat named Cinnamon and compared her DNA to genomes from six other domestic cat breeds, two wild cat species, and to the genome of a tiger, dog, cow, and human.

Many of the genes identified as changed in domestic cats have been linked to reward responses, memory and fear conditioning, studies in mice have shown. The genome changes suggest cats became tame as they became less fearful of humans and more responsive to being rewarded with food.

The feline genetic code also offered insight into how cats evolved away from other mammals.

Compared to omnivorous humans and herbivorous cows, carnivorous cats appear to have more quickly evolved genes that bestow an enhanced ability to digest heavy fats found in meat. A study in polar bears published earlier this year found the same genetic adaptation in the DNA of the meat-loving Arctic bear.

In addition, by comparing cat and dog genomes, the researchers found a unique evolutionary trade-off between the two groups: While dogs evolved an unsurpassed sense of smell, cats traded in those smell receptor genes for genes that enhanced their ability to sense pheromones, odorless substances that enable animals of the same species to communicate, such as to find a mate.

Go here to read the rest:
If Your Cat Doesnt Like You Much, Blame Its Genome

Genetics and rule of probability

By: Nikolay #39;s Genetics Lessons

Read more:
Genetics and rule of probability - Video

Gene Therapy for Treating Cancer
Gene Therapy for Treating Cancer.

By: WTNH News8

Read the original here:
Gene Therapy for Treating Cancer - Video

Spinal cord injuryTow surfing! Line of sight
GOPROTRY.

By:

Continue reading here:
Spinal cord injuryTow surfing! Line of sight - Video

What Is The Definition Of Spinal cord injury Medical School Terminology Dictionary
Visit our website for text version of this Definition and app download. http://www.medicaldictionaryapps.com Subjects: medical terminology, medical dictionary, medical dictionary free download,...

By: Medical Dictionary Online

More here:
What Is The Definition Of Spinal cord injury Medical School Terminology Dictionary - Video

Modeling Human Disease - Panel Discussion
The increasing ease with which accessible cells (e.g., blood, skin) from a given patient can be reprogrammed and redirected to assume the phenotype of a dise...

By: Alliance for Regenerative Medicine

Read the rest here:
Modeling Human Disease - Panel Discussion - Video

Rafael Nadal's doctor says the 14-time grand slam winner will receive stem cell treatment on his ailing back.

Angel Ruiz-Cotorro told AP by phone on Monday that "we are going to put cells in a joint in his spine" next week in Barcelona.

The Spanish tennis star was already sidelined for the rest of the season after having his appendix removed last week.

Ruiz-Cotorro, who has worked as a doctor for Nadal for the past 14 years, said Nadal's back pain is "typical of tennis" players and that the treatment is meant to help repair his cartilage and is similar to stem cell treatment Nadal received on his knee last year.

He said Nadal is expected to return to training in early December.

Several NFL players and baseball players have received stem cell treatment.

Nadal's fellow Spaniard Pau Gasol, centre of the Chicago Bulls, received stem cell treatment on his knee in 2013.

Nadal experienced severe back pain during the final of the Australian Open in January when he lost to Stanislas Wawrinka.

"(Nadal) has a problem typical in tennis with a back joint, he had it at the Australian Open, and we have decided to treat it with stem cells," Ruiz-Cotorro said.

He said that stem cells were recently extracted from Nadal for a cultivation process to "produce the necessary quantities."

See the rest here:
Nadal to receive stem cell treatment

Clinical Trials: Advanced Cell Technology - Stem Cell Therapy
Last month (October 2014) in The Lancet, Advanced Cell Technology (ACT) published their preliminary phase 1 clinical data for their Stem Cell therapy trials for Stargardt #39;s Macular Dystrophy...

By: Essceejulies

Original post:
Clinical Trials: Advanced Cell Technology - Stem Cell Therapy - Video

Magnifisio dashed home strongly over 1400m to win Saturdays Lee-Steere Stakes at Ascot. Picture: Westernracepix

Sprinter Smoko will have stem cell therapy at Murdoch Veterinary Hospital to a strained suspensory ligament in his off-foreleg.

Vets found Smoko had strained the ligament when he pulled up sore following his shock sixth as a $2 favourite to Shining Knight in last Tuesday's Colonel Reeves Stakes (1100m) at Ascot.

Co-trainer Ross Price said Smoko would be sidelined for months.

"He will go to Murdoch where they will look at him and see about stem cell therapy," he said.

"In about 10 days we will take him up there and see what they can do. It is then going to be five months off and hoping."

Smoko was a $6.50 chance in Saturday week's Winterbottom Stakes (1200m) before he was scratched. WA's hopes of winning back the Group 1 weight-for-age hinge on Magnifisio, Shining Knight and Testamezzo, with Barakey in doubt after struggling to recover from a virus.

"He is still feeling flat and I will have to wait and see if he improves over the next few days," trainer Jim Taylor said.

Magnifisio firmed from $12 into $8 on the TAB yesterday following her strong win at her debut over 1400m in Saturday's Group 2 Lee-Steere Stakes at Ascot.

Melbourne sprinters Angelic Light, Moment Of Change and reigning champion Buffering dominate betting at $4.30, $6.50 and $7.50.

Continue reading here:
Stem cell therapy for sidelined star Smoko

The day Olivia Cox was diagnosed with Type 1 diabetes at age 16, her mother vowed to find a cure.

"I said to her, "there's someone walking this Earth who has been cured of diabetes, and I'm going to find him," Ruth Cox said.

Cox's search started with a call to Harvard University and ended with a family trip to Lima, Peru. It was at a clinic there that now 18-year-old Olivia and her father, Jeff, 54, who also has diabetes, received an infusion of stem cells designed to wipe out diabetes in their bodies or, at the very least, lessen its impact. The treatment illegal in the United States cost $70,000 for both father and daughter. Two months later, the Niskayuna family is waiting for a transformation and wondering if, in their desperation for a cure, they were snookered by false promises.

Because stem cells can be programmed to become anything from heart muscle to toenails, stem cell therapy can hypothetically be used to treat anything, from baldness to Lou Gehrig's Disease. But the study of regenerative medicine is still nascent in the United States, where it is restricted to procedures that use the patient's own cells, and it has been primarily used in treating cancer a procedure that saved Ruth Cox 13 years ago, when she had breast cancer.

Stem cell treatment using donor cells is more common elsewhere in the world, but with varying results and none that could be described as a cure. An executive order from President Barack Obama opened up funding for stem cell research and there are now more than 4,000 clinical trials under way, some on animals and some recruiting people with various ailments.

The American Diabetes Association strongly supports stem cell research, according to a statement posted on its website, which reads in part:

"Scientists from across the United States and throughout the world, including those involved with the American Diabetes Association believe that stem cell research, especially embryonic stem cell research, holds great promise in the search for a cure and better treatments for diabetes."

Jeff Cox, diagnosed with Type 1 diabetes when he was 11, has suffered none of the complications that often come with the disease neuropathy, loss of vision and heart disease. But Cox said living with diabetes is hell. He pricks his finger at least a dozen times a day to check his blood sugar level, because it is a more precise reading than the glucose monitor he wears. He also wears a pump that he programs to inject him with insulin automatically based on his diet and exercise each day. All the therapies used to treat diabetes are designed to intervene where the pancreas has gone awry.

In Type 1 diabetes, the pancreas doesn't produce insulin due to an autoimmune attack against the beta cell that produces insulin the hormone that converts glucose into energy our bodies need to survive. The Coxes didn't want their daughter to face a lifetime of managing her diabetes. They wanted a cure, and they were willing to take a risk to find it.

In order to treat diabetes with stem cell therapy, pancreatic stem cells isolated from umbilical cord blood that are programmed to produce insulin, plus autologous mesenchymal stem cells from the patient's bone marrow, are injected. Once in the pancreas, the cells are supposed to replicate themselves, gradually replacing the non-insulin producing cells in the host's pancreas. The treatment is conducted in Peru, China, Russia and India and elsewhere, but Zubin Master, a bioethicist at Albany Medical College, said the risks of traveling abroad for stem cell therapy range from paying for an expensive treatment that doesn't work, to cancer and death.

See original here:
Family's desperate bet on a diabetes cure